Ambrx, a San Diego biotech developing antibody-drug conjugates to treat solid tumors and other diseases, said today it is withdrawing its planned IPO because of current market conditions. The company had planned to raise as much as $86 million in an IPO, according to a confidential filing that was made public in early May.
Help employers find you! Check out all the jobs and post your resume.
